Potent Activation of NAD-Dependent Deacetylase Sirt7 by Nucleosome Binding
Overview
Biology
Affiliations
Sirtuin-7 (Sirt7) is a nuclear NAD-dependent deacetylase with a broad spectrum of biological functions. Sirt7 overexpression is linked to several pathological states and enhances anticancer drug resistance, making the enzyme a promising target for the development of novel therapeutics. Despite a plethora of reported functions, the biochemical characterization of recombinant Sirt7 remains inadequate for the development of novel drug candidates. Here, we conduct an extensive biochemical analysis of Sirt7 using newly developed binding and kinetic assays to reveal that the enzyme preferentially interacts with and is activated by nucleosomes. Sirt7 activation by nucleic acids alone is effective toward long-chain acylated hydrophobic substrates, while only nucleosome binding leads to 10-fold activation of the deacetylase activity. Using endogenous chromatin and recombinant acetylated nucleosomes, we reveal that Sirt7 is one of the most efficient deacetylases in the sirtuin family and that its catalytic activity is limited by the rate of dissociation from deacetylated nucleosomes.
Structural basis of SIRT7 nucleosome engagement and substrate specificity.
Moreno-Yruela C, Ekundayo B, Foteva P, Ni D, Calvino-Sanles E, Stahlberg H Nat Commun. 2025; 16(1):1328.
PMID: 39900593 PMC: 11790868. DOI: 10.1038/s41467-025-56529-y.
Activation and inhibition of sirtuins: From bench to bedside.
Fiorentino F, Fabbrizi E, Mai A, Rotili D Med Res Rev. 2024; 45(2):484-560.
PMID: 39215785 PMC: 11796339. DOI: 10.1002/med.22076.
YZL-51N functions as a selective inhibitor of SIRT7 by NAD competition to impede DNA damage repair.
Kang T, Yan Y, Tian Y, Zhang J, Zhang M, Shu Y iScience. 2024; 27(6):110014.
PMID: 38947512 PMC: 11214487. DOI: 10.1016/j.isci.2024.110014.
Current Trends in Sirtuin Activator and Inhibitor Development.
Bursch K, Goetz C, Smith B Molecules. 2024; 29(5).
PMID: 38474697 PMC: 10934002. DOI: 10.3390/molecules29051185.